Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – McMahon Website

James B. McMahon, Ph.D.

Selected Publications

1)  Woldemichael GM, Vasselli JR, Gardella RS, McKee TC, Linehan WM, McMahon JB.
Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression.
J Biomol Screen. 11: 678-87, 2006.
2)  Henrich CJ, Robey RW, Bokesch HR, Bates SE, Shukla S, Ambudkar SV, Dean M, McMahon JB.
New inhibitors of ABCG2 identified by high-throughput screening.
Mol. Cancer Ther. 6: 3271-8, 2007.
3)  Kang MI, Henrich CJ, Bokesch HR, Gustafson KR, McMahon JB, Baker AR, Young MR, Colburn NH.
A selective small-molecule nuclear factor-kappaB inhibitor from a high-throughput cell-based assay for.
Mol. Cancer Ther. 8: 571-81, 2009.
4)  Woldemichael GM, Turbyville TJ, Linehan WM, McMahon JB.
Carminomycin I is an apoptosis inducer that targets the Golgi complex in clear cell renal carcinoma cells.
Cancer Res. 71: 134-42, 2011.
5)  Woldemichael GM, Turbyville TJ, Vasselli JR, Linehan WM, McMahon JB.
Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A.
Neoplasia. 14: 771-7, 2012.
6)  Bajer MM, Kunze MM, Blees JS, Bokesch HR, Chen H, Brauss TF, Dong Z, Gustafson KR, Biondi RM, Henrich CJ, McMahon JB, Colburn NH, Schmid T, Brüne B.
Characterization of pomiferin triacetate as a novel mTOR and translation inhibitor.
Biochem. Pharmacol. 88: 313-21, 2014.
7)  Devkota KP, Wilson JA, Henrich CJ, McMahon JB, Reilly KM, Beutler JA.
Compounds from Simarouba berteroana which inhibit proliferation of NF1-defective cancer cells.
Phytochem Lett. 7: 42-45, 2014.
8)  Dull AB, George AA, Goncharova EI, Evans JR, Wamiru A, Cartner LK, Hager GL, McMahon JB.
Identification of compounds by high-content screening that induce cytoplasmic to nuclear localization of a fluorescent estrogen receptor a chimera and exhibit agonist or antagonist activity in vitro.
J Biomol Screen. 19: 242-52, 2014.
9)  Beutler J.
Koehn F, eds.
Natural Products as Tools for Discovering New Cancer Targets. In: Natural Products and Cancer Drug Discovery.
New York: Humana Press; 2013. p. 213-237 [Book Chapter]
10)  Kanduluru AK, Banerjee P, Beutler JA, Fuchs PL.
A Convergent Total Synthesis of the Potent Cephalostatin/Ritterazine Hybrid -25-epi Ritterostatin GN1N.
J. Org. Chem. 78: 9085-92, 2013.
Click Here to View Expanded Bibliography.

This page was last updated on 6/17/2014.